I see AbbVie has recently sponsored a clinical trial titled "A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) (TRAVERSE)". The trial started May 3rd, 2018 and has an estimated patient population of 6000 men and completion date of June 30, 2022.
Hard to believe that AbbVie would not be interested in the female population, especially since the Libigel Efficacy/Safety Trial data produced a 70% reduction in CV events and an unknown percentage of Breast Cancer events.
Remember, AbbVie picked up the Priority Review Voucher (PRV) for $350 Million the August 19, 2015 the day after Addyi became the first FDA approved drug to treat HSSD (Pre-menopauasl women only). Analyst theorized a number of intended uses, yet all the drugs that analysts believed the PRV was intended for have gone through NDA filing and AbbVie has still not used the PRV.
Neither AbbVie nor Ani Pharmaceuticals have hinted at a deal. However I find it hard to believe that AbbVie would risk letting another company including a collaborator, such as Allergan, in the above trial come in and scoop up Libigel (or whatever it will be called). Especially after hiring Dr Snabes directly from Biosante upon completion of the first phase of the Libigel trial.
It also justifies AbbVie hiring Dr Scott as their Chief Medical Officer who has a strong cardiovascular back ground.
2019 should tell whether it has been n elaborate series of coincidences or a well orchestrated plan.
Prediction for 2019. If a deal is announced, AbbVie will assume a stake in Ani Pharmaceuticals and be given one of the two seats on the BOD presently occupied by MVP and Ani will continue to grow.
News 
Market Data 
Discover 
